A paucity of versatile small animal models of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection has been an impediment to both furthering understanding of virus biology and testing antiviral therapies. We recently described a regulatable system for repopulating the liver of immunodeficient mice (specifically mice lacking fumaryl acetoacetate hydrolase [Fah], recombination activating gene 2 [Rag2], and the γ-chain of the receptor for IL-2 [Il-2rγ]) with human hepatocytes. Here we have shown that a high transplantation dose (3 × 10⁶ to 5 × 10⁶ human hepatocytes/mouse) generates a higher rate of liver chimerism than was previously obtained in these mice, up to 95% human hepatocyte chimerism. Mice with a high level of human liver chimerism propagated both HBV and HCV, and the HCV-infected mice were responsive to antiviral treatment. This human liver chimeric mouse model will expand the experimental possibilities for studying HBV and HCV infection, and possibly other human hepatotropic pathogens, and prove useful for antiviral drug testing.

Introduction
HBV is the prototype for the Hepadnaviridae family of hepatotropic, partially double-stranded DNA viruses (1), while HCV is a single-stranded RNA virus in the Flaviviridae family (2). Although structural (C, E1, E2, p7) and nonstructural proteins (NS2–5) (2). a single polyprotein precursor, which is eventually cleaved into DNA intermediates within the viral capsid. In contrast, the HCV tropic, partially double-stranded DNA viruses (1), while HCV is a

Results
Robust repopulation with human hepatocytes. To undertake infections with hepatotropic human viruses, we first devised novel strategies to increase the extent of human hepatocyte reconstitution in Fab⁻/⁻Rag2⁻/⁻Il2rg⁻/⁻ mice. This involved primarily increasing

Conflict of interest: The authors have declared that no conflict of interest exists.
Citation for this article: J Clin Invest. 2010;120(3):924–930. doi:10.1172/JCI40094.
the number of transplanted human hepatocytes (see Methods for details). Briefly, we transplanted 50 animals with $3 \times 10^6$ to $5 \times 10^6$ human hepatocytes from 12 different donors (4–67 years; Supplemental Table 1; supplemental material available online with this article; doi:10.1172/JCI40094DS1) and with no pretreatment other than NTBC. Table 1 shows that in 50 reconstituted mice, an average human albumin level of 7.6 mg/ml was detected in the mouse serum. Based on quantitative morphometry of FAH-positive, human hepatocytes in the mouse liver, this corresponds to a chimerism of 42% (see also Figure 1F). These levels were about 10–100 times higher than previously reported (16). Figure 1, A–D, shows a highly repopulated mouse with near complete humanization of the mouse liver as evidenced by immunostaining for FAH and human-specific cytokeratin 18 antibodies. It thus appears that high human chimerism can be achieved in our $Fab^+\text{Rag}^2\text{Il2rg}^-$ mouse strain by simply transplanting more human hepatocytes.

Since human albumin is a convenient, noninvasive marker for human hepatocyte repopulation, we analyzed the correlation between human albumin levels in the murine serum and immunostaining for FAH. Figure 1F shows a good correlation by regression analysis ($r^2 = 0.88$). Therefore, only a few microliters of murine blood are needed for estimating human hepatocyte repopulation.

**HBV infection in human liver chimeric mice.** We inoculated 4 highly repopulated mice with HBV (see Methods). After 6 weeks, maximal serum titers of up to $8.15 \times 10^8$ genome equivalents (GE)/ml were observed. Analysis of liver tissue at 2 and 7 weeks after inoculation confirmed intrahepatic propagation and revealed a commensurate increase in HBV cccDNA (from 1.2 to 98 copies/ng human liver

---

### Table 1

<table>
<thead>
<tr>
<th>Mice ($n$)</th>
<th>Mean HSA level (mg/ml)</th>
<th>Average human liver chimerism (%)$^a$</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>0.8</td>
<td>2.6</td>
</tr>
<tr>
<td>4</td>
<td>3.1</td>
<td>15.8</td>
</tr>
<tr>
<td>10</td>
<td>5.1</td>
<td>27.5</td>
</tr>
<tr>
<td>4</td>
<td>7.6</td>
<td>42.1</td>
</tr>
<tr>
<td>5</td>
<td>8.6</td>
<td>48.4</td>
</tr>
<tr>
<td>10</td>
<td>10.7</td>
<td>60.6</td>
</tr>
<tr>
<td>4</td>
<td>12.7</td>
<td>72.6</td>
</tr>
<tr>
<td>3</td>
<td>14.9</td>
<td>85.3</td>
</tr>
<tr>
<td>2</td>
<td>16.9</td>
<td>96.9</td>
</tr>
<tr>
<td>Total, 50</td>
<td>Average, 7.6</td>
<td>Average, 42.4</td>
</tr>
</tbody>
</table>

$^a$Average human liver chimerism is given as function of the correlation between human serum albumin (HSA) and FAH immunostaining (Figure 1F) and was confirmed (±10%) by anti-FAH immunostaining in each group.

---

**Figure 1**

Nearly complete repopulation of the $Fab^+\text{Rag}^2\text{Il2rg}^-$ mouse liver with human hepatocytes. (A–E) Immunostaining of the same liver for FAH (A and B), human-specific cytokeratin-18 (C and D), and no primary antibody (control, E). (B and D) Higher-magnification views of the boxed areas in A and C, respectively. Scale bars: 1 mm (A, C, and E), 50 μm (B and D). (F) Correlation of human albumin level in the murine serum and repopulation as assessed by morphometry of FAH immunostaining. A, C, and E are composite images.
other HCV genotypes, we inoculated 2 chimeric mice with a clinical isolate of HCV genotype 1a and 1 mouse each with 2 different genotypes — the chimeric HCV viruses 1a/2a and 1b/2a (H77/C3 and Con1/C3) — that are infectious in vitro (18). Figure 3B shows that all the different HCV genotypes could be propagated in chimeric mice. Intriguingly, there was a 1,000-fold difference in titers between the clinical sample (mouse 164 and 193) and the chimeric HCV genomes (mouse 205 and 206). The successful propagation of all 4 different HCV viruses could be confirmed by the detection of HCV RNA in total liver RNA (Figure 3C). Like HCV RNA levels in the serum, intrahepatic HCV RNA levels normalized for human GAPDH did not correlate with human serum albumin levels and hence replication rates. Liver tissue of chimeric mice was stained for HCV nonstructural protein 5A (NS5a) and FAH. Figure 3, E–G, shows that immunostaining for NS5a colocalized with human hepatocytes that were FAH positive. Histological examination did not reveal any cytopathic effect of HCV infection (data not shown). In a few chimeric livers, we observed hepatocellular carcinoma, exclusively originating from mouse tissue. Hence, these tumors reflect a known complication of tyrosinemia type I rather than virus-related tumor growth (19).

Antiviral therapy in human liver chimeric mice. To extend the utility of this animal model, we explored its suitability for evaluation of antiviral drug efficacy. The state-of-the-art therapy against HCV is the combination of pegylated interferon α 2a (peg-IFN) and the nucleoside analog ribavirin. We compared this therapy to a more experimental therapy in clinical evaluation (19), the cyclophilin inhibitor Debio 025. We set up 1 control group without treatment and 3 treatment groups (peg-IFN alone, peg-IFN and ribavirin, peg-IFN and Debio 025). The control group received saline injections and oral gavages of the vehicle only. All 12 animals (4 × 3 mice) had high human liver chimerism and were inoculated with a clinical isolate of HCV genotype 1a. Antiviral therapy was performed for 2 weeks, after animals had reached the plateau phase of HCV titer (day 21). All treated animals showed an approximately 3 log reduction in HCV RNA after 2 weeks of treatment (Figure 3D). We also inoculated 2 mice with a clinical isolate of HCV genotype 3a, which is known to be more sensitive to interferon. Indeed viral titers decreased even further than those of HCV genotype 1a upon peg-IFN treatment (Supplemental Figure 3). All treatments were well tolerated by all animals.

We investigated yet another class of antiviral compounds, this time in human liver chimeric mice infected with HBV. The nucleo-
tide analog adefovir dipivoxil, which is used in the treatment of HBV patients, could lower the HBV titers in the murine serum (Supplemental Methods and Supplemental Figure 4).

Sustained viral propagation in human liver chimeric mice. To evaluate long-term infection, we inoculated 6 animals with HCV genotype 1 and monitored them for more than half a year (34 weeks). Three of the 6 mice had been treated with the peg-IFN and Debio 025 for 4 weeks. Five to 6 weeks after antiviral therapy was ceased, the mean HCV levels of the treatment group were again comparable to those of the nontreated ones and reached plateau phase for the remainder of the study (Figure 4A).

Encouraged by this long-term propagation in human liver chimeric mice, we were interested to see whether the virus could also be passed from one chimeric mouse to another. We inoculated 2 mice with a clinical sample of HCV genotype 1a (Figure 4B). After 4 weeks, we used their serum to inoculate 2 different mice by diluting the virus to match the titer of the clinical inoculum (Figure 4C). The HCV RNA levels of the 4 mice were comparable in terms of maximal viral titer and kinetics of early infection.

Some of the chimeric mice used for HBV and HCV infection were repopulated with hepatocytes from the same donor (Supplemental Tables 1 and 2) and therefore offered the possibility to compare viral infection under standardized host conditions. Supplemental Figure 5 shows HBV and HCV infection in chimeric mice of the same hepatocyte donor (44-year-old, mixed European descent) and exemplifies the differences in viral dynamics not only between HBV and HCV, but also between different HCV isolates.

Discussion
We describe in this study the propagation of hepatotropic viruses in human liver chimeric mice. In a series of experiments using more than 60 chimeric Fah−/−Rag2−/−Il2rg−/− mice, we have estab-
lished the conditions for successful HBV and HCV infection. In these animals, the selection pressure for transplanted human hepatocytes can be regulated by the drug NTBC, in the absence of which mouse hepatocytes die due to the accumulation of toxic tyrosine catabolites caused by the lack of FAH, while human hepatocytes stay healthy due to the human homolog. This leads to a growth disadvantage for mouse hepatocytes and positive selection for transplanted human hepatocytes. The human cells expand and can repopulate up to approximately 95% of the murine liver. The advantage of this regulatable system is that animals with low human chimerism can be put back on the drug NTBC and hence do not undergo liver failure and eventually death. Our study reveals that even minimally repopulated chimeric mice (human serum albumin, 0.04–0.16 mg/ml) can be productively infected by HBV, reflecting the highly infectious nature of HBV and/or the high rate of HBV production by each infected hepatocyte.

Mice with low human chimerism (<10%) could not be infected with HCV (data not shown). We reasoned that high chimerism would solve that problem and therefore optimized repopulation rates. We show that a high initial hepatocyte dose (3 × 10⁶ to 5 × 10⁶ per mouse) is sufficient to reproducibly generate high human chimerism. We and others reported the transplantation of up to 1 × 10⁶ human hepatocytes in the Fah–/–Rag2–/–Il2rg–/– mouse (15, 16). If the engraftment rate is linear, this low dose should expand to approximately 3 × 10⁶ to 5 × 10⁶ hepatocytes (i.e., the high hepatocyte transplantation dose reported herein) after only 2 cell cycles in the murine liver. However, in our hands, most of the mice transplanted with a low cell dose never reached high repopulation rates.

Mice with high human chimerism do not need to be maintained on NTBC and have a human albumin level greater than 2 mg/ml, which corresponds to a human repopulation rate of greater than 10% (morphometry for FAH immunostaining). While HBV can infect livers largely independently of the extent of human chimerism, successful HCV infection can only be established in high human chimerism, which was reached 2–6 months after transplantation. When we inoculated highly repopulated mice with HCV, we were able to infect with a variety of different HCV strains (Figure 3 and Supplemental Figure 3). Infection with the clinical HCV genotype 1a isolate yielded the highest titers (up to 10⁶ GE/ml). This probably reflects genotype differences and not differences in the repopulation rates, since there was no correlation between serum albumin and HCV RNA levels (Figure 3C). Our study also demonstrates that intergenotypic (1a/2a and 1b/2a) chimeric viruses are infectious and can propagate in vivo.

Further, we show that this animal model is suitable for candidate antiviral drug screening. We compared the state-of-the-art treatment (peg-IFN and ribavirin) for HCV with a novel combination therapy (peg-IFN and Debio 025) (20) in the clinically most-challenging HCV genotype 1. Although no significant difference could be found among the treatment groups, our results demonstrate the feasibility and effectiveness of antiviral treatment in this chimeric mouse model. Further, we recapitulated the differences in interferon sensitivity of HCV genotype 1a and 3a.

We further show that viral propagation in these chimeric animals can be sustained for more than half a year and most likely does not have any impact on the animal’s health. HCV can also be passaged from one chimeric mouse to another with viral titers and dynamics similar to those achieved with inoculation with patient serum.

In summary, this study introduces a new in vivo animal model for the study of hepatotropic viruses. Further, we show that a high cell dose is sufficient for reproducibly generating mice with high human liver chimerism. The results along with the relative ease of handling the chimeric Fah–/–Rag2–/–Il2rg–/– mouse suggest that this model will greatly expand the experimental possibilities for the study of HBV and HCV infection and the evaluation of antiviral drugs.

**Methods**

*Mice.* All animal studies were reviewed and approved by the IACUC of the Salk Institute for Biological Studies. Fah–/–Rag2–/–Il2rg–/– mice (mixed background: C57BL/6 and 129Sv) were kept on 7.5 mg/l NTBC (100%) in the...
drinking water and in temperature- and humidity-controlled animal quarters with a 12-hour light/12-hour dark cycle. Besides NTBC and the antiviral therapy described below, no other drugs were used during the entire study.

Transplantation of human hepatocytes. Hepatocytes were purchased from CellzDirect. Hepatocytes were shipped as cell pellets on ice in the provided medium. Upon arrival, cells were washed once with 50 ml HBMM (Lonza) and kept on ice until transplantation (within 48 hours after isolation). Two- to 4-month-old mice underwent transplantation as previously described (16), except that the cell dose was increased to 3 × 10^5 to 5 × 10^5 hepatocytes per mouse. NTBC was withdrawn in a stepwise fashion: 2 successive days at 25%, then 12%, and then 6% of colony maintenance concentration (7.5 mg/l), prior to termination of drug therapy. After 2–6 weeks, mice with clinical symptoms (lethargy, hunched posture) or severe weight loss were put again on NTBC for 3 days before second withdrawal (cycling). Cycling was repeated until clinical symptoms resolved. Chimeric mice that were treated with peg-IFN (Pegasys, Roche Inc.) twice a week at 30 mg/kg by gavage; Debiopharm SA) or ribavirin (daily 10 mg/kg by subcutaneously alone or in combination with either Debio 025 (daily at 5 GE/ml HCV genotype 1a (or genotype 2a)) or interferon (PEG-Intron A, Schering-Plough) for 8 weeks, were treated with NTBC (N-acetyl-L-cysteine) at 6% (or 12%) of colony maintenance concentration and kept on ice until transplantation (within 48 hours after isolation).

Inoculation with HBV and HCV. Chimeric Fah–/–Rag2–/–Il2rg–/– mice were injected with 1 × 10^6 GE HBV, genotype D (serotype ayw) into the tail vein. The inoculum was derived from the serum of an HBV-infected chimpanzee (21) and diluted in PBS to a volume of 200 μl.

For HCV, the following doses per mouse were used for intravenous inoculation: 100 μl Huh-7 cell culture supernatants diluted in 100 μl PBS containing 2 × 10^5 ffu JFH-1 (22), 3 × 10^4 ffu HCV Con1/C3 (18), 3 × 10^5 ffu HCV H77/ C3 (18) and 100 μl of patient serum containing 2 × 10^5 GE/ml HCV genotype 1a or 2 × 10^4 IU/ml HCV genotype 3a diluted in PBS to a volume of 200 μl.

Antiviral therapy. Fah–/–Rag2–/–Il2rg–/– mice with high chimerism were injected in the tail vein with 2 × 10^6 GE HCV genotype 1a (or genotype 3a) diluted in PBS to a volume of 200 μl. Where indicated, animals were treated with peg-IFN (Pegasys, Roche Inc.) twice a week at 30 mg/kg subcutaneously alone or in combination with either Debo 025 (daily at 100 mg/kg by gavage; Debiopharm SA) or ribavirin (daily 10 mg/kg by gavage; Toronto Research Chemicals Inc.). Control animals were treated twice a week with injection of 100 μl saline subcutaneously and daily gavage of the vehicle only.

Serological and blood analysis. Serum was harvested by orbital-breedaloring and stored in aliquots for further analysis. Human albumin in the murine blood was assayed by ELISA (Bethyl Laboratories) according to the manufacturer's manual. Serum dilutions of 10- to 10,000-fold were used to get values within the linear range of the standard curve.

HBV DNA was extracted from 50 μl serum by proteinase K digestion as previously described (23), and serum HBV DNA levels were analyzed by real-time quantitative PCR (QPCR) using HBV-specific primers as previously described (24).

HCV RNA was extracted from 50 μl serum by a modified guanidine thiocyanate method exactly as previously described (23), and serum HCV RNA levels were analyzed by RT-QPCR using HCV-specific primers as previously described (22).

Immunostaining. Liver tissue was harvested and either fixed in 4% paraformaldehyde for subsequent immunostaining or immediately snap-frozen for RNA and DNA extraction. Paraffin-embedded sections of fixed liver were dewaxed and rehydrated through xylene and decreasing concentrations of ethanol. The sections were incubated with primary antibodies (monoclonal mouse anti-FAH [1:5,000; gift from Robert M. Tanguay, Université Laval, Quebec City, Canada] or polyclonal goat anti-FAH [1:100, Santa Cruz Biotechnology Inc.]), monoclonal mouse anti-cytokeratin 18 (Dako), polyclonal rabbit anti-HBc-Ag (1:4,000; Dako) overnight or with polyclonal rabbit anti–HCV NS5a (gift of M. Houghton, Chiron, Emeryville, California) for 1 hour. Immunoreactivity was assessed either with a streptavidin-biotin amplification and diaminobenzidine or with fluorescently labeled secondary antibodies (counterstaining with DAPI) for the double staining (counterstaining with hematoxylin).

Detection of HBV and HCV intermediates in the liver. For HBV cccDNA and HBV DNA replicative intermediate analysis, frozen liver tissue was homogenized as previously described (24). Ninety percent of the homogenate was used to extract cccDNA, and the rest of the homogenate was used to extract total liver DNA as previously described (24). HBV cccDNA and replicative intermediates were analyzed by real-time QPCR using HBV-specific primers as previously described (24). The percentage of human DNA was determined by QPCR for the mouse and human GIMAPI gene as previously described (25), and HBV DNA copy numbers per nanogram of total liver DNA were normalized for the percentage of human IMAP. For intrahepatic RNA analysis, total liver RNA was isolated by a modified guanidine thiocyanate method exactly as previously described (26). HBV, HCV, and human and mouse GAPDH RNA was quantified in 1 μg total RNA by real-time RT-PCR using virus- and gene-specific primers as previously described (22), and HCV and HBV RNA copy numbers per nanogram of total liver RNA were normalized for the percentage of human GAPDH.

Statistics. Data are shown as mean ± SD or mean ± range. The statistical differences of results were analyzed by Kruskal-Wallis test using the GraphPad Prism program. P values of 0.05 or less were considered significant.

Acknowledgments. The authors thank Joe Chambers, Jacob Lopez, and Christina Whitten for technical assistance; Konrad Streetz for valuable discussions; and Gerald Pao for critical reading of the manuscript. This work was supported by grants to I.M. Verma from the American Cancer Society, the NIH (NHLBI H53670), the Leducq Foundation, the Ellison Medical Foundation, Ipsen Biomeasure, Sanofi-Aventis, and the H.N. and Frances C. Berger Foundation; and grants to F.V. Chisari from the NIH (R01-AI20001 and R01-CA40489). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NHLBI or the NIH.

Received for publication June 5, 2009, and accepted in revised form December 9, 2009.

Address correspondence to: Inder M. Verma, Salk Institute for Biological Studies, Laboratory of Genetics, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA. Phone: 858.558.4100 ext. 1462; Fax: 858.558.7454; E-mail: verma@salk.edu.

11. Yang PL, Altalhe A, Chung J, Chisari FV. Hydrog